Global Candidiasis Market

Candidiasis Comprehensive Study by Type (Candida Infections of the Mouth, Throat, and Esophagus, Vaginal Candidiasis, Invasive/Systemic Candidiasis), Route of Administration (Oral, Parenteral, Topical), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), Drug Class (Azoles, Echinocandins, Polyenes, Flucytosine) Players and Region - Global Market Outlook to 2030

Candidiasis Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Candidiasis
Candidiasis is a fungal infection caused by a yeast (a type of fungus) called Candida. Some species of Candida can cause infection in people; the most common is Candida albicans. Candida normally lives on skin and inside the body, such as the mouth, throat, gut, and vagina, without causing problems. The candidiasis market is expected to register significant growth as various research institutes are focused on developing novel drugs. Candidiasis is a type of infection caused due to yeast. It is usually present in places such as the mouth, belly, and on the skin. There are various types of infections caused due to candidiasis such as thrush/ oropharyngeal candidiasis, genital yeast infection/ invasive infection, and cutaneous candidiasis.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)


The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Candidiasis market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Basilea Pharmaceutica AG (Switzerland), Astellas Pharma Inc. (Japan), Grupo Ferrer Internacional, S.A. (Spain), Pacgen Life Science Corporation (Canada), NovaDigm Therapeutics, Inc. (United States), Cidara Therapeutics, Inc. (United States), Amplyx Pharmaceuticals Inc. (United States) and Pfizer (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are GlaxoSmithKline plc (United Kingdom), Bayer AG (Germany), Merck & Co., Inc (United States) and Johnson & Johnson Services, Inc. (United States).

Segmentation Overview
AMA Research has segmented the market of Global Candidiasis market by Type (Candida Infections of the Mouth, Throat, and Esophagus, Vaginal Candidiasis and Invasive/Systemic Candidiasis) and Region.



On the basis of geography, the market of Candidiasis has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Route of Administration, the sub-segment i.e. Oral will boost the Candidiasis market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Distribution Channel, the sub-segment i.e. Hospital Pharmacies will boost the Candidiasis market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Drug Class, the sub-segment i.e. Azoles will boost the Candidiasis market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Growing Awareness for Candidiasis

Market Growth Drivers:
Increasing Number of Invasive Candidiasis and Vaginal Candidiasis Cases and Rising Number of Preterm Births

Challenges:
Stringent Government Regulations

Restraints:
Increasing Adoption of Alternative Therapies

Opportunities:
Increasing Research and Development of Novel Treatments and High Investment in Healthcare

Market Leaders and their expansionary development strategies
In October 2023, GlaxoSmithKline joins forces with academic institutions to establish a research consortium focusing on the development of new antifungal drugs and vaccines against Candida.
In November 2023, Novo Nordisk launches a long-acting injectable antifungal medication for severe invasive candidiasis, reducing the need for frequent intravenous administration.


Key Target Audience
Manufactures of Drugs for Candidiasis, Pharmaceuticals Companies, Industry Associations, Government and Private Research Organization, Government Regulatory Bodies, End-User Industries and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Candida Infections of the Mouth, Throat, and Esophagus
  • Vaginal Candidiasis
  • Invasive/Systemic Candidiasis
By Route of Administration
  • Oral
  • Parenteral
  • Topical

By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Drug Class
  • Azoles
  • Echinocandins
  • Polyenes
  • Flucytosine

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Number of Invasive Candidiasis and Vaginal Candidiasis Cases
      • 3.2.2. Rising Number of Preterm Births
    • 3.3. Market Challenges
      • 3.3.1. Stringent Government Regulations
    • 3.4. Market Trends
      • 3.4.1. Growing Awareness for Candidiasis
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Candidiasis, by Type, Route of Administration, Distribution Channel, Drug Class and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Candidiasis (Value)
      • 5.2.1. Global Candidiasis by: Type (Value)
        • 5.2.1.1. Candida Infections of the Mouth, Throat, and Esophagus
        • 5.2.1.2. Vaginal Candidiasis
        • 5.2.1.3. Invasive/Systemic Candidiasis
      • 5.2.2. Global Candidiasis by: Route of Administration (Value)
        • 5.2.2.1. Oral
        • 5.2.2.2. Parenteral
        • 5.2.2.3. Topical
      • 5.2.3. Global Candidiasis by: Distribution Channel (Value)
        • 5.2.3.1. Hospital Pharmacies
        • 5.2.3.2. Retail Pharmacies
        • 5.2.3.3. Online Pharmacies
      • 5.2.4. Global Candidiasis by: Drug Class (Value)
        • 5.2.4.1. Azoles
        • 5.2.4.2. Echinocandins
        • 5.2.4.3. Polyenes
        • 5.2.4.4. Flucytosine
      • 5.2.5. Global Candidiasis Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Candidiasis: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Basilea Pharmaceutica AG (Switzerland)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Astellas Pharma Inc. (Japan)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Grupo Ferrer Internacional, S.A. (Spain)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Pacgen Life Science Corporation (Canada)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. NovaDigm Therapeutics, Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Cidara Therapeutics, Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Amplyx Pharmaceuticals Inc. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Pfizer (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
  • 7. Global Candidiasis Sale, by Type, Route of Administration, Distribution Channel, Drug Class and Region (value) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Candidiasis (Value)
      • 7.2.1. Global Candidiasis by: Type (Value)
        • 7.2.1.1. Candida Infections of the Mouth, Throat, and Esophagus
        • 7.2.1.2. Vaginal Candidiasis
        • 7.2.1.3. Invasive/Systemic Candidiasis
      • 7.2.2. Global Candidiasis by: Route of Administration (Value)
        • 7.2.2.1. Oral
        • 7.2.2.2. Parenteral
        • 7.2.2.3. Topical
      • 7.2.3. Global Candidiasis by: Distribution Channel (Value)
        • 7.2.3.1. Hospital Pharmacies
        • 7.2.3.2. Retail Pharmacies
        • 7.2.3.3. Online Pharmacies
      • 7.2.4. Global Candidiasis by: Drug Class (Value)
        • 7.2.4.1. Azoles
        • 7.2.4.2. Echinocandins
        • 7.2.4.3. Polyenes
        • 7.2.4.4. Flucytosine
      • 7.2.5. Global Candidiasis Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Candidiasis: by Type(USD Million)
  • Table 2. Candidiasis Candida Infections of the Mouth, Throat, and Esophagus , by Region USD Million (2018-2023)
  • Table 3. Candidiasis Vaginal Candidiasis , by Region USD Million (2018-2023)
  • Table 4. Candidiasis Invasive/Systemic Candidiasis , by Region USD Million (2018-2023)
  • Table 5. Candidiasis: by Route of Administration(USD Million)
  • Table 6. Candidiasis Oral , by Region USD Million (2018-2023)
  • Table 7. Candidiasis Parenteral , by Region USD Million (2018-2023)
  • Table 8. Candidiasis Topical , by Region USD Million (2018-2023)
  • Table 9. Candidiasis: by Distribution Channel(USD Million)
  • Table 10. Candidiasis Hospital Pharmacies , by Region USD Million (2018-2023)
  • Table 11. Candidiasis Retail Pharmacies , by Region USD Million (2018-2023)
  • Table 12. Candidiasis Online Pharmacies , by Region USD Million (2018-2023)
  • Table 13. Candidiasis: by Drug Class(USD Million)
  • Table 14. Candidiasis Azoles , by Region USD Million (2018-2023)
  • Table 15. Candidiasis Echinocandins , by Region USD Million (2018-2023)
  • Table 16. Candidiasis Polyenes , by Region USD Million (2018-2023)
  • Table 17. Candidiasis Flucytosine , by Region USD Million (2018-2023)
  • Table 18. South America Candidiasis, by Country USD Million (2018-2023)
  • Table 19. South America Candidiasis, by Type USD Million (2018-2023)
  • Table 20. South America Candidiasis, by Route of Administration USD Million (2018-2023)
  • Table 21. South America Candidiasis, by Distribution Channel USD Million (2018-2023)
  • Table 22. South America Candidiasis, by Drug Class USD Million (2018-2023)
  • Table 23. Brazil Candidiasis, by Type USD Million (2018-2023)
  • Table 24. Brazil Candidiasis, by Route of Administration USD Million (2018-2023)
  • Table 25. Brazil Candidiasis, by Distribution Channel USD Million (2018-2023)
  • Table 26. Brazil Candidiasis, by Drug Class USD Million (2018-2023)
  • Table 27. Argentina Candidiasis, by Type USD Million (2018-2023)
  • Table 28. Argentina Candidiasis, by Route of Administration USD Million (2018-2023)
  • Table 29. Argentina Candidiasis, by Distribution Channel USD Million (2018-2023)
  • Table 30. Argentina Candidiasis, by Drug Class USD Million (2018-2023)
  • Table 31. Rest of South America Candidiasis, by Type USD Million (2018-2023)
  • Table 32. Rest of South America Candidiasis, by Route of Administration USD Million (2018-2023)
  • Table 33. Rest of South America Candidiasis, by Distribution Channel USD Million (2018-2023)
  • Table 34. Rest of South America Candidiasis, by Drug Class USD Million (2018-2023)
  • Table 35. Asia Pacific Candidiasis, by Country USD Million (2018-2023)
  • Table 36. Asia Pacific Candidiasis, by Type USD Million (2018-2023)
  • Table 37. Asia Pacific Candidiasis, by Route of Administration USD Million (2018-2023)
  • Table 38. Asia Pacific Candidiasis, by Distribution Channel USD Million (2018-2023)
  • Table 39. Asia Pacific Candidiasis, by Drug Class USD Million (2018-2023)
  • Table 40. China Candidiasis, by Type USD Million (2018-2023)
  • Table 41. China Candidiasis, by Route of Administration USD Million (2018-2023)
  • Table 42. China Candidiasis, by Distribution Channel USD Million (2018-2023)
  • Table 43. China Candidiasis, by Drug Class USD Million (2018-2023)
  • Table 44. Japan Candidiasis, by Type USD Million (2018-2023)
  • Table 45. Japan Candidiasis, by Route of Administration USD Million (2018-2023)
  • Table 46. Japan Candidiasis, by Distribution Channel USD Million (2018-2023)
  • Table 47. Japan Candidiasis, by Drug Class USD Million (2018-2023)
  • Table 48. India Candidiasis, by Type USD Million (2018-2023)
  • Table 49. India Candidiasis, by Route of Administration USD Million (2018-2023)
  • Table 50. India Candidiasis, by Distribution Channel USD Million (2018-2023)
  • Table 51. India Candidiasis, by Drug Class USD Million (2018-2023)
  • Table 52. South Korea Candidiasis, by Type USD Million (2018-2023)
  • Table 53. South Korea Candidiasis, by Route of Administration USD Million (2018-2023)
  • Table 54. South Korea Candidiasis, by Distribution Channel USD Million (2018-2023)
  • Table 55. South Korea Candidiasis, by Drug Class USD Million (2018-2023)
  • Table 56. Taiwan Candidiasis, by Type USD Million (2018-2023)
  • Table 57. Taiwan Candidiasis, by Route of Administration USD Million (2018-2023)
  • Table 58. Taiwan Candidiasis, by Distribution Channel USD Million (2018-2023)
  • Table 59. Taiwan Candidiasis, by Drug Class USD Million (2018-2023)
  • Table 60. Australia Candidiasis, by Type USD Million (2018-2023)
  • Table 61. Australia Candidiasis, by Route of Administration USD Million (2018-2023)
  • Table 62. Australia Candidiasis, by Distribution Channel USD Million (2018-2023)
  • Table 63. Australia Candidiasis, by Drug Class USD Million (2018-2023)
  • Table 64. Rest of Asia-Pacific Candidiasis, by Type USD Million (2018-2023)
  • Table 65. Rest of Asia-Pacific Candidiasis, by Route of Administration USD Million (2018-2023)
  • Table 66. Rest of Asia-Pacific Candidiasis, by Distribution Channel USD Million (2018-2023)
  • Table 67. Rest of Asia-Pacific Candidiasis, by Drug Class USD Million (2018-2023)
  • Table 68. Europe Candidiasis, by Country USD Million (2018-2023)
  • Table 69. Europe Candidiasis, by Type USD Million (2018-2023)
  • Table 70. Europe Candidiasis, by Route of Administration USD Million (2018-2023)
  • Table 71. Europe Candidiasis, by Distribution Channel USD Million (2018-2023)
  • Table 72. Europe Candidiasis, by Drug Class USD Million (2018-2023)
  • Table 73. Germany Candidiasis, by Type USD Million (2018-2023)
  • Table 74. Germany Candidiasis, by Route of Administration USD Million (2018-2023)
  • Table 75. Germany Candidiasis, by Distribution Channel USD Million (2018-2023)
  • Table 76. Germany Candidiasis, by Drug Class USD Million (2018-2023)
  • Table 77. France Candidiasis, by Type USD Million (2018-2023)
  • Table 78. France Candidiasis, by Route of Administration USD Million (2018-2023)
  • Table 79. France Candidiasis, by Distribution Channel USD Million (2018-2023)
  • Table 80. France Candidiasis, by Drug Class USD Million (2018-2023)
  • Table 81. Italy Candidiasis, by Type USD Million (2018-2023)
  • Table 82. Italy Candidiasis, by Route of Administration USD Million (2018-2023)
  • Table 83. Italy Candidiasis, by Distribution Channel USD Million (2018-2023)
  • Table 84. Italy Candidiasis, by Drug Class USD Million (2018-2023)
  • Table 85. United Kingdom Candidiasis, by Type USD Million (2018-2023)
  • Table 86. United Kingdom Candidiasis, by Route of Administration USD Million (2018-2023)
  • Table 87. United Kingdom Candidiasis, by Distribution Channel USD Million (2018-2023)
  • Table 88. United Kingdom Candidiasis, by Drug Class USD Million (2018-2023)
  • Table 89. Netherlands Candidiasis, by Type USD Million (2018-2023)
  • Table 90. Netherlands Candidiasis, by Route of Administration USD Million (2018-2023)
  • Table 91. Netherlands Candidiasis, by Distribution Channel USD Million (2018-2023)
  • Table 92. Netherlands Candidiasis, by Drug Class USD Million (2018-2023)
  • Table 93. Rest of Europe Candidiasis, by Type USD Million (2018-2023)
  • Table 94. Rest of Europe Candidiasis, by Route of Administration USD Million (2018-2023)
  • Table 95. Rest of Europe Candidiasis, by Distribution Channel USD Million (2018-2023)
  • Table 96. Rest of Europe Candidiasis, by Drug Class USD Million (2018-2023)
  • Table 97. MEA Candidiasis, by Country USD Million (2018-2023)
  • Table 98. MEA Candidiasis, by Type USD Million (2018-2023)
  • Table 99. MEA Candidiasis, by Route of Administration USD Million (2018-2023)
  • Table 100. MEA Candidiasis, by Distribution Channel USD Million (2018-2023)
  • Table 101. MEA Candidiasis, by Drug Class USD Million (2018-2023)
  • Table 102. Middle East Candidiasis, by Type USD Million (2018-2023)
  • Table 103. Middle East Candidiasis, by Route of Administration USD Million (2018-2023)
  • Table 104. Middle East Candidiasis, by Distribution Channel USD Million (2018-2023)
  • Table 105. Middle East Candidiasis, by Drug Class USD Million (2018-2023)
  • Table 106. Africa Candidiasis, by Type USD Million (2018-2023)
  • Table 107. Africa Candidiasis, by Route of Administration USD Million (2018-2023)
  • Table 108. Africa Candidiasis, by Distribution Channel USD Million (2018-2023)
  • Table 109. Africa Candidiasis, by Drug Class USD Million (2018-2023)
  • Table 110. North America Candidiasis, by Country USD Million (2018-2023)
  • Table 111. North America Candidiasis, by Type USD Million (2018-2023)
  • Table 112. North America Candidiasis, by Route of Administration USD Million (2018-2023)
  • Table 113. North America Candidiasis, by Distribution Channel USD Million (2018-2023)
  • Table 114. North America Candidiasis, by Drug Class USD Million (2018-2023)
  • Table 115. United States Candidiasis, by Type USD Million (2018-2023)
  • Table 116. United States Candidiasis, by Route of Administration USD Million (2018-2023)
  • Table 117. United States Candidiasis, by Distribution Channel USD Million (2018-2023)
  • Table 118. United States Candidiasis, by Drug Class USD Million (2018-2023)
  • Table 119. Canada Candidiasis, by Type USD Million (2018-2023)
  • Table 120. Canada Candidiasis, by Route of Administration USD Million (2018-2023)
  • Table 121. Canada Candidiasis, by Distribution Channel USD Million (2018-2023)
  • Table 122. Canada Candidiasis, by Drug Class USD Million (2018-2023)
  • Table 123. Mexico Candidiasis, by Type USD Million (2018-2023)
  • Table 124. Mexico Candidiasis, by Route of Administration USD Million (2018-2023)
  • Table 125. Mexico Candidiasis, by Distribution Channel USD Million (2018-2023)
  • Table 126. Mexico Candidiasis, by Drug Class USD Million (2018-2023)
  • Table 127. Company Basic Information, Sales Area and Its Competitors
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Candidiasis: by Type(USD Million)
  • Table 136. Candidiasis Candida Infections of the Mouth, Throat, and Esophagus , by Region USD Million (2025-2030)
  • Table 137. Candidiasis Vaginal Candidiasis , by Region USD Million (2025-2030)
  • Table 138. Candidiasis Invasive/Systemic Candidiasis , by Region USD Million (2025-2030)
  • Table 139. Candidiasis: by Route of Administration(USD Million)
  • Table 140. Candidiasis Oral , by Region USD Million (2025-2030)
  • Table 141. Candidiasis Parenteral , by Region USD Million (2025-2030)
  • Table 142. Candidiasis Topical , by Region USD Million (2025-2030)
  • Table 143. Candidiasis: by Distribution Channel(USD Million)
  • Table 144. Candidiasis Hospital Pharmacies , by Region USD Million (2025-2030)
  • Table 145. Candidiasis Retail Pharmacies , by Region USD Million (2025-2030)
  • Table 146. Candidiasis Online Pharmacies , by Region USD Million (2025-2030)
  • Table 147. Candidiasis: by Drug Class(USD Million)
  • Table 148. Candidiasis Azoles , by Region USD Million (2025-2030)
  • Table 149. Candidiasis Echinocandins , by Region USD Million (2025-2030)
  • Table 150. Candidiasis Polyenes , by Region USD Million (2025-2030)
  • Table 151. Candidiasis Flucytosine , by Region USD Million (2025-2030)
  • Table 152. South America Candidiasis, by Country USD Million (2025-2030)
  • Table 153. South America Candidiasis, by Type USD Million (2025-2030)
  • Table 154. South America Candidiasis, by Route of Administration USD Million (2025-2030)
  • Table 155. South America Candidiasis, by Distribution Channel USD Million (2025-2030)
  • Table 156. South America Candidiasis, by Drug Class USD Million (2025-2030)
  • Table 157. Brazil Candidiasis, by Type USD Million (2025-2030)
  • Table 158. Brazil Candidiasis, by Route of Administration USD Million (2025-2030)
  • Table 159. Brazil Candidiasis, by Distribution Channel USD Million (2025-2030)
  • Table 160. Brazil Candidiasis, by Drug Class USD Million (2025-2030)
  • Table 161. Argentina Candidiasis, by Type USD Million (2025-2030)
  • Table 162. Argentina Candidiasis, by Route of Administration USD Million (2025-2030)
  • Table 163. Argentina Candidiasis, by Distribution Channel USD Million (2025-2030)
  • Table 164. Argentina Candidiasis, by Drug Class USD Million (2025-2030)
  • Table 165. Rest of South America Candidiasis, by Type USD Million (2025-2030)
  • Table 166. Rest of South America Candidiasis, by Route of Administration USD Million (2025-2030)
  • Table 167. Rest of South America Candidiasis, by Distribution Channel USD Million (2025-2030)
  • Table 168. Rest of South America Candidiasis, by Drug Class USD Million (2025-2030)
  • Table 169. Asia Pacific Candidiasis, by Country USD Million (2025-2030)
  • Table 170. Asia Pacific Candidiasis, by Type USD Million (2025-2030)
  • Table 171. Asia Pacific Candidiasis, by Route of Administration USD Million (2025-2030)
  • Table 172. Asia Pacific Candidiasis, by Distribution Channel USD Million (2025-2030)
  • Table 173. Asia Pacific Candidiasis, by Drug Class USD Million (2025-2030)
  • Table 174. China Candidiasis, by Type USD Million (2025-2030)
  • Table 175. China Candidiasis, by Route of Administration USD Million (2025-2030)
  • Table 176. China Candidiasis, by Distribution Channel USD Million (2025-2030)
  • Table 177. China Candidiasis, by Drug Class USD Million (2025-2030)
  • Table 178. Japan Candidiasis, by Type USD Million (2025-2030)
  • Table 179. Japan Candidiasis, by Route of Administration USD Million (2025-2030)
  • Table 180. Japan Candidiasis, by Distribution Channel USD Million (2025-2030)
  • Table 181. Japan Candidiasis, by Drug Class USD Million (2025-2030)
  • Table 182. India Candidiasis, by Type USD Million (2025-2030)
  • Table 183. India Candidiasis, by Route of Administration USD Million (2025-2030)
  • Table 184. India Candidiasis, by Distribution Channel USD Million (2025-2030)
  • Table 185. India Candidiasis, by Drug Class USD Million (2025-2030)
  • Table 186. South Korea Candidiasis, by Type USD Million (2025-2030)
  • Table 187. South Korea Candidiasis, by Route of Administration USD Million (2025-2030)
  • Table 188. South Korea Candidiasis, by Distribution Channel USD Million (2025-2030)
  • Table 189. South Korea Candidiasis, by Drug Class USD Million (2025-2030)
  • Table 190. Taiwan Candidiasis, by Type USD Million (2025-2030)
  • Table 191. Taiwan Candidiasis, by Route of Administration USD Million (2025-2030)
  • Table 192. Taiwan Candidiasis, by Distribution Channel USD Million (2025-2030)
  • Table 193. Taiwan Candidiasis, by Drug Class USD Million (2025-2030)
  • Table 194. Australia Candidiasis, by Type USD Million (2025-2030)
  • Table 195. Australia Candidiasis, by Route of Administration USD Million (2025-2030)
  • Table 196. Australia Candidiasis, by Distribution Channel USD Million (2025-2030)
  • Table 197. Australia Candidiasis, by Drug Class USD Million (2025-2030)
  • Table 198. Rest of Asia-Pacific Candidiasis, by Type USD Million (2025-2030)
  • Table 199. Rest of Asia-Pacific Candidiasis, by Route of Administration USD Million (2025-2030)
  • Table 200. Rest of Asia-Pacific Candidiasis, by Distribution Channel USD Million (2025-2030)
  • Table 201. Rest of Asia-Pacific Candidiasis, by Drug Class USD Million (2025-2030)
  • Table 202. Europe Candidiasis, by Country USD Million (2025-2030)
  • Table 203. Europe Candidiasis, by Type USD Million (2025-2030)
  • Table 204. Europe Candidiasis, by Route of Administration USD Million (2025-2030)
  • Table 205. Europe Candidiasis, by Distribution Channel USD Million (2025-2030)
  • Table 206. Europe Candidiasis, by Drug Class USD Million (2025-2030)
  • Table 207. Germany Candidiasis, by Type USD Million (2025-2030)
  • Table 208. Germany Candidiasis, by Route of Administration USD Million (2025-2030)
  • Table 209. Germany Candidiasis, by Distribution Channel USD Million (2025-2030)
  • Table 210. Germany Candidiasis, by Drug Class USD Million (2025-2030)
  • Table 211. France Candidiasis, by Type USD Million (2025-2030)
  • Table 212. France Candidiasis, by Route of Administration USD Million (2025-2030)
  • Table 213. France Candidiasis, by Distribution Channel USD Million (2025-2030)
  • Table 214. France Candidiasis, by Drug Class USD Million (2025-2030)
  • Table 215. Italy Candidiasis, by Type USD Million (2025-2030)
  • Table 216. Italy Candidiasis, by Route of Administration USD Million (2025-2030)
  • Table 217. Italy Candidiasis, by Distribution Channel USD Million (2025-2030)
  • Table 218. Italy Candidiasis, by Drug Class USD Million (2025-2030)
  • Table 219. United Kingdom Candidiasis, by Type USD Million (2025-2030)
  • Table 220. United Kingdom Candidiasis, by Route of Administration USD Million (2025-2030)
  • Table 221. United Kingdom Candidiasis, by Distribution Channel USD Million (2025-2030)
  • Table 222. United Kingdom Candidiasis, by Drug Class USD Million (2025-2030)
  • Table 223. Netherlands Candidiasis, by Type USD Million (2025-2030)
  • Table 224. Netherlands Candidiasis, by Route of Administration USD Million (2025-2030)
  • Table 225. Netherlands Candidiasis, by Distribution Channel USD Million (2025-2030)
  • Table 226. Netherlands Candidiasis, by Drug Class USD Million (2025-2030)
  • Table 227. Rest of Europe Candidiasis, by Type USD Million (2025-2030)
  • Table 228. Rest of Europe Candidiasis, by Route of Administration USD Million (2025-2030)
  • Table 229. Rest of Europe Candidiasis, by Distribution Channel USD Million (2025-2030)
  • Table 230. Rest of Europe Candidiasis, by Drug Class USD Million (2025-2030)
  • Table 231. MEA Candidiasis, by Country USD Million (2025-2030)
  • Table 232. MEA Candidiasis, by Type USD Million (2025-2030)
  • Table 233. MEA Candidiasis, by Route of Administration USD Million (2025-2030)
  • Table 234. MEA Candidiasis, by Distribution Channel USD Million (2025-2030)
  • Table 235. MEA Candidiasis, by Drug Class USD Million (2025-2030)
  • Table 236. Middle East Candidiasis, by Type USD Million (2025-2030)
  • Table 237. Middle East Candidiasis, by Route of Administration USD Million (2025-2030)
  • Table 238. Middle East Candidiasis, by Distribution Channel USD Million (2025-2030)
  • Table 239. Middle East Candidiasis, by Drug Class USD Million (2025-2030)
  • Table 240. Africa Candidiasis, by Type USD Million (2025-2030)
  • Table 241. Africa Candidiasis, by Route of Administration USD Million (2025-2030)
  • Table 242. Africa Candidiasis, by Distribution Channel USD Million (2025-2030)
  • Table 243. Africa Candidiasis, by Drug Class USD Million (2025-2030)
  • Table 244. North America Candidiasis, by Country USD Million (2025-2030)
  • Table 245. North America Candidiasis, by Type USD Million (2025-2030)
  • Table 246. North America Candidiasis, by Route of Administration USD Million (2025-2030)
  • Table 247. North America Candidiasis, by Distribution Channel USD Million (2025-2030)
  • Table 248. North America Candidiasis, by Drug Class USD Million (2025-2030)
  • Table 249. United States Candidiasis, by Type USD Million (2025-2030)
  • Table 250. United States Candidiasis, by Route of Administration USD Million (2025-2030)
  • Table 251. United States Candidiasis, by Distribution Channel USD Million (2025-2030)
  • Table 252. United States Candidiasis, by Drug Class USD Million (2025-2030)
  • Table 253. Canada Candidiasis, by Type USD Million (2025-2030)
  • Table 254. Canada Candidiasis, by Route of Administration USD Million (2025-2030)
  • Table 255. Canada Candidiasis, by Distribution Channel USD Million (2025-2030)
  • Table 256. Canada Candidiasis, by Drug Class USD Million (2025-2030)
  • Table 257. Mexico Candidiasis, by Type USD Million (2025-2030)
  • Table 258. Mexico Candidiasis, by Route of Administration USD Million (2025-2030)
  • Table 259. Mexico Candidiasis, by Distribution Channel USD Million (2025-2030)
  • Table 260. Mexico Candidiasis, by Drug Class USD Million (2025-2030)
  • Table 261. Research Programs/Design for This Report
  • Table 262. Key Data Information from Secondary Sources
  • Table 263. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Candidiasis: by Type USD Million (2018-2023)
  • Figure 5. Global Candidiasis: by Route of Administration USD Million (2018-2023)
  • Figure 6. Global Candidiasis: by Distribution Channel USD Million (2018-2023)
  • Figure 7. Global Candidiasis: by Drug Class USD Million (2018-2023)
  • Figure 8. South America Candidiasis Share (%), by Country
  • Figure 9. Asia Pacific Candidiasis Share (%), by Country
  • Figure 10. Europe Candidiasis Share (%), by Country
  • Figure 11. MEA Candidiasis Share (%), by Country
  • Figure 12. North America Candidiasis Share (%), by Country
  • Figure 13. Global Candidiasis share by Players 2023 (%)
  • Figure 14. Global Candidiasis share by Players (Top 3) 2023(%)
  • Figure 15. Global Candidiasis share by Players (Top 5) 2023(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Basilea Pharmaceutica AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 18. Basilea Pharmaceutica AG (Switzerland) Revenue: by Geography 2023
  • Figure 19. Astellas Pharma Inc. (Japan) Revenue, Net Income and Gross profit
  • Figure 20. Astellas Pharma Inc. (Japan) Revenue: by Geography 2023
  • Figure 21. Grupo Ferrer Internacional, S.A. (Spain) Revenue, Net Income and Gross profit
  • Figure 22. Grupo Ferrer Internacional, S.A. (Spain) Revenue: by Geography 2023
  • Figure 23. Pacgen Life Science Corporation (Canada) Revenue, Net Income and Gross profit
  • Figure 24. Pacgen Life Science Corporation (Canada) Revenue: by Geography 2023
  • Figure 25. NovaDigm Therapeutics, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 26. NovaDigm Therapeutics, Inc. (United States) Revenue: by Geography 2023
  • Figure 27. Cidara Therapeutics, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 28. Cidara Therapeutics, Inc. (United States) Revenue: by Geography 2023
  • Figure 29. Amplyx Pharmaceuticals Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 30. Amplyx Pharmaceuticals Inc. (United States) Revenue: by Geography 2023
  • Figure 31. Pfizer (United States) Revenue, Net Income and Gross profit
  • Figure 32. Pfizer (United States) Revenue: by Geography 2023
  • Figure 33. Global Candidiasis: by Type USD Million (2025-2030)
  • Figure 34. Global Candidiasis: by Route of Administration USD Million (2025-2030)
  • Figure 35. Global Candidiasis: by Distribution Channel USD Million (2025-2030)
  • Figure 36. Global Candidiasis: by Drug Class USD Million (2025-2030)
  • Figure 37. South America Candidiasis Share (%), by Country
  • Figure 38. Asia Pacific Candidiasis Share (%), by Country
  • Figure 39. Europe Candidiasis Share (%), by Country
  • Figure 40. MEA Candidiasis Share (%), by Country
  • Figure 41. North America Candidiasis Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Basilea Pharmaceutica AG (Switzerland)
  • Astellas Pharma Inc. (Japan)
  • Grupo Ferrer Internacional, S.A. (Spain)
  • Pacgen Life Science Corporation (Canada)
  • NovaDigm Therapeutics, Inc. (United States)
  • Cidara Therapeutics, Inc. (United States)
  • Amplyx Pharmaceuticals Inc. (United States)
  • Pfizer (United States)
Additional players considered in the study are as follows:
GlaxoSmithKline plc (United Kingdom) , Bayer AG (Germany) , Merck & Co., Inc (United States) , Johnson & Johnson Services, Inc. (United States)
Select User Access Type

Key Highlights of Report


Jan 2024 228 Pages 73 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Candidiasis Market Quantitative research analysis
Global Candidiasis Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Basilea Pharmaceutica AG (Switzerland), Astellas Pharma Inc. (Japan), Grupo Ferrer Internacional, S.A. (Spain), Pacgen Life Science Corporation (Canada), NovaDigm Therapeutics, Inc. (United States), Cidara Therapeutics, Inc. (United States), Amplyx Pharmaceuticals Inc. (United States) and Pfizer (United States) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Growing Awareness for Candidiasis" is seen as one of major influencing trends for Candidiasis Market during projected period 2023-2030.
The Candidiasis market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Candidiasis Market Report?

Have a Query? Click Here

Other Related Reports

Capillariasis Comprehensive Study by Type (Capillaria Hepatica, Capillaria Philippinensis), Application (Hospitals, Clinics, Homecare), Testing Type (Microscopy, Serologic Tests, Proteomics Testing),...
$ 3450
Multiple Myeloma Therapy Comprehensive Study by Type (Targeted Therapy, Chemotherapy, Radiotherapy, Bone Marrow Transplant), Application (Smouldering Multiple Myeloma, Active Multiple Myeloma), End-U...
$ 3350
Gynecologic Cancer Comprehensive Study by Type (Uterine Cancer, Ovarian Cancer, Vaginal Cancer, Vulvar Cancer, Cervical Cancer), Application (Hospital, Clinic, Other), Treatment (Chemotherapy, Rad...
$ 3650
Campylobacter Diagnostics Comprehensive Study by Type (Culture-based Diagnosis, Rapid Detection Tests (Immunological, Molecular, and Other )), End User (Hospitals, Private Laboratories, Independent P...
$ 3350
Brucellosis Comprehensive Study by Transmission (Raw Dairy Products, Inhaling Contaminated Air, Infected Blood & Body Fluids, Others), Diagnosis (Serological Tests, Molecular Techniques, Bone Marrow ...
$ 3750
Carrion's Disease Comprehensive Study by Antibiotics (Chloramphenicol, Azithromycin, Erythromycin, Ciprofloxacin, Rifampin, Macrolides), Stages (Acute Phase, Chronic Phase), End User (Hospitals, Clin...
$ 3500